Hire an Advanced Robo-Advisor to Trade ILMN on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Smart Auto-Trading?
Smart Auto-Trading is an advanced Robo-Trader designed to provides investors with a trading partner to automate systematic investing. Its robo is designed to screen, monitor and auto-trade elite stocks like ILLUMINA, INC. (ILMN) using Artificial Intelligence, social media and market data to augments your potential as an investor.
Smart Auto-Trading produces short-term trades which makes it ideal for trading in tax-deferred accounts such as IRA, SIMPLE IRA, Rollover IRA, 529 College Plans, Keoghs and UGMAs. It also works in taxable accounts. Just be aware that if you elect to auto-trade using Smart Auto-Trading in a regular brokerage account, you will be taxed at regular income. Make sure you understand your tax situation before using Smart Auto-trading.
Using Smart Auto-Trading is easy. It connects to your brokerage account at Ally Invest, one of the most trusted broker/dealer in the United States. All you need to do is open an account with them, put a minimum of $25,000 in your account and connect Smart Auto-Trading to trade.
There are clear benefits associated with using a Robo-Trader such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few easy steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Robo investing really means that a computer program is tasked to monitor and trade stocks based on your carefully crafted strategy.
Robo investing simplifies stock investing by processing and organizing stocks for the purpose of trading.
Once your strategy is set up, all you need to do is start your simulation. The Robo-Trader then executes your strategy by finding and trading stocks that meet specific requirements.
Because you can test and improve your strategy over time, the AI empowers you to find the appropriate strategy without risking your capital.
Time is your ally when it comes down to AI investing. Take your time to refine your simulation and learn about the capabilities of the technology. Patterns will reveal themselves and empower you to develop your real potential.
Smart Auto-Trading is one of the first Robo-Trader to take advantage of Government grade listening technology, Artificial Intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Traders like other investment methods rely on favorable market conditions to provide positive outcomes.
ILLUMINA, INC. (ILMN) News
Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis
Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
DRAGEN can be run on premise, in the cloud, or in a hybrid mode, and is flexible and compatible for use with multiple cloud storage solutions and analysis pipelines. Edico Genome has built a strong base of NGS customers who have incorporated DRAGEN as a standard part of their sequencing workflow.
“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” said Susan Tousi, Senior Vice President of Product Development at Illumina. “We expect to build on the solid foundation of DRAGEN to deliver a more streamlined and integrated sample to answer experience for our customers.”
The DRAGEN platform complements Illumina’s sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times, to improve their overall efficiency and to allow greater emphasis on interpretation and reporting.
“The scientific community should align around standards to maximize the impact of genomics in health,” said Anthony Philippakis, MD, PhD, Chief Data Officer of the Broad Institute of MIT and Harvard. “We are excited to collaborate with Illumina on approaches and pipelines for the analysis of NGS data. The Genome Analysis Toolkit (GATK) has been adopted by a diverse set of researchers, and we look forward to integrating these methods with Illumina sequencers to improve the overall efficiency of data analysis—enabling the community to more easily share and collaborate.”
“Thanks to Illumina, the ability to generate accurate and affordable sequencing data is rapidly expanding the market and use cases for NGS. As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing,” said Pieter van Rooyen PhD, President and CEO of Edico Genome. “Our team is invigorated at the prospect of joining Illumina to combine our respective strengths to streamline and accelerate secondary analysis for the genomics community.”
“We have had tremendous success at Rady’s for years using Edico’s DRAGEN coupled with Illumina sequencers to accelerate the delivery of genomic insights for critically ill newborns,” said Stephen F. Kingsmore, MD, DSc, President and CEO of Rady Children’s Institute for Genomic Medicine. “Our goal is to ensure that whole-genome sequencing is available to every child who needs it. To do this, we need a rapid workflow that can scale and ultimately be accessible to hospitals around the world.”Get Started today! - Risk Free